Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 2, 2002, Pages 147-151

  Vlasoff, Dmitry M ^a   Baschinsky, Dmitry Y ^a   Frankel, Wendy L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cytokeratin; Cytokeratin 5 6; Hepatobiliary neoplasms; Hepatocellular carcinoma; Pancreatic neoplasms

Indexed keywords

CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 6; UNCLASSIFIED DRUG; KERATIN;

ADENOCARCINOMA; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER TUMOR; MESOTHELIOMA; PANCREAS TUMOR; PRIORITY JOURNAL; BILIARY TRACT TUMOR; CLASSIFICATION; METABOLISM; PATHOLOGY;

BILIARY TRACT NEOPLASMS; HUMAN; IMMUNOHISTOCHEMISTRY; KERATIN; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; HUMANS; KERATINS;

EID: 0036001201     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200206000-00009     Document Type: Article

References (27)

1. Immunohistochemistry in the differential diagnosis of liver carcinomas
2. Primary vs. metastatic hepatic carcinoma. An immunohistochemical study of 34 cases
3. Immunocytochemical staining of fine needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma
4. Albumin gene expression in liver tumors: Diagnostic interest in fine needle aspiration biopsies
5. Combined hepatocellular and cholangiocarcinoma. Proposed criteria according to cytokeratin expression and analysis of clinicopathological features
6. Histogenesis of primary liver carcinomas: Strengths and weaknesses of cytokeratin profile and albumin mRNA detection
7. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of the liver
8. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma
9. Value of mesothelium associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to pleura
10. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma
11. Cytokeratin immunohistochemistry assists in differential diagnosis of atypical proliferations of the breast
12. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers
13. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors
14. HepPar 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumors and metastatic carcinoma
15. The significance of alphafetoprotein and other tumor markers in differential immunohistochemistry of primary liver tumors
16. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver
17. Hepatocellular carcinoma, adenoma and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters
18. Coordinate expression of cytokeratins 7 and 20 defines unique subset of carcinomas
19. Cytokeratin profile of extrahepatic pancreatobiliary epithelia and their carcinomas
20. Intermediate filaments as differentiation markers of normal pancreas and pancreatic cancer
21. Molecular diversity of cytokeratins: Significance for cell and tumor differentiation
22. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells
23. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies
24. Keratin immunohistochemistry: Update of applications and pitfalls
25. Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas
26. Use of monoclonal antibody to keratin 7 in the differential diagnosis of adenocarcinomas
27. The expression of cytokeratins 7, 19 and 20 in primary and metastatic carcinomas of the liver